Scandinavian ChemoTech proceeds to the second round of “Horizon 2020” and is awarded a 50 000 EUR contribution
The ChemoTech D-EECP project for pain treatment of patients suffering from metastases in the spine, proceeds to the second round of “Horizon 2020” and is awarded a 50 000 Euro contribution to cover application costs for phase 2.Horizon 2020 is the most extensive EU program for research and innovation ever. The purpose of the program is to achieve more breakthroughs, discoveries and world news by supporting good ideas from the lab to advance to the market. The process includes several steps, where the first is a 50 000 EUR contribution to cover application costs. ChemoTech will receive